NVCR
NovoCure Ltd
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
Actual EPS |
---|
Consensus EPS |
Estimated EPS |
Number of Estimates |
EPS Surprise |
Stats
Summary
we are a commercial-stage oncology company developing a novel, proprietary therapy called tumor treating fields, or ttfields, for the treatment of solid tumor cancers. we count on the contributions of our talented team members who are committed to improving the lives of cancer patients. here at novocure, cancer patients and their families are – and have always been – at the core of our mission. we expect our colleagues to excel, and in return, we invest in their professional growth and personal well-being. we seek high performers who thrive in fast-paced environments and are inspired by making a difference in cancer care. we offer employment opportunities in the u.s., europe and asia.
Market Cap: 1.78 Billion
Primary Exchange: NASDAQ
Website: https://www.novocure.com/
Shares Outstanding: 107 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.6171980549958598
Sector: Manufacturing
Industry: Surgical and Medical Instrument Manufacturing
Ethical Flags
Longest drawdown: 852 trading days
From: 2021-06-23 To: 2024-03-07
Lowest Point:
Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
---|
Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
---|